GlassScriptPhysician profile
Asha Prabhu
NPI 1376634550
$2,305.53
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $353 · 2021: $454 · 2022: $435 · 2023: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $298.82 | 2019-2023 | Aristada, Lybalvi |
| Abbvie INC. | $297.74 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $276.84 | 2019-2023 | Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $225.63 | 2019-2022 | |
| Lundbeck LLC | $221.44 | 2019-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $157.14 | 2019-2022 | |
| Allergan, INC. | $150.29 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $133.20 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $121.56 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.04 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $104.77 | 2019-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $98.60 | 2021-2022 | |
| Corium, LLC | $53.25 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $31.71 | 2023 | |
| Shire North American Group INC | $14.46 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Prabhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.